Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Post by dollarhunteron Nov 12, 2003 5:52pm

244 Views

Post# 6641088

EQUITY FINANCING

Couldn't help but notice Canaccord buying up everything today pushing the price to .46. Is it possible we could see a new round of equity financing before the 16th of Dec.? On another note I re-read the news release from back during the Oxiquant merger [Nov 4 '02] and noticed an indication of the possibilities of a 4 to 1 reverse split for the purpose of accessing capital markets with the timing of such a split to be determined whenever the company thought needed. Could this be the time? If so then is this a good time to exit and then re-enter with more free shares at a lower price after any possible dilution from another round of financing? Or would a 4 for 1 reverse split help hold the price stable? Any thoughts? DH

Bullboard Posts

How one company is disrupting PoC testing